DE202014011208U1 - C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind - Google Patents

C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind Download PDF

Info

Publication number
DE202014011208U1
DE202014011208U1 DE202014011208.8U DE202014011208U DE202014011208U1 DE 202014011208 U1 DE202014011208 U1 DE 202014011208U1 DE 202014011208 U DE202014011208 U DE 202014011208U DE 202014011208 U1 DE202014011208 U1 DE 202014011208U1
Authority
DE
Germany
Prior art keywords
esterase inhibitor
composition
administration
hae
units
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE202014011208.8U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viropharma Biologics LLC
Original Assignee
Shire Viropharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE202014011208(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma LLC filed Critical Shire Viropharma LLC
Publication of DE202014011208U1 publication Critical patent/DE202014011208U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE202014011208.8U 2013-03-15 2014-03-17 C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind Expired - Lifetime DE202014011208U1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15
US201361791399P 2013-03-15

Publications (1)

Publication Number Publication Date
DE202014011208U1 true DE202014011208U1 (de) 2018-08-23

Family

ID=51538486

Family Applications (1)

Application Number Title Priority Date Filing Date
DE202014011208.8U Expired - Lifetime DE202014011208U1 (de) 2013-03-15 2014-03-17 C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind

Country Status (30)

Country Link
US (9) US9616111B2 (https=)
EP (3) EP3290046B1 (https=)
JP (9) JP6184581B2 (https=)
KR (4) KR102430453B1 (https=)
CN (2) CN111529708A (https=)
AU (3) AU2014232912A1 (https=)
BR (1) BR112015023207A8 (https=)
CA (2) CA3054718A1 (https=)
CY (2) CY1119419T1 (https=)
DE (1) DE202014011208U1 (https=)
DK (2) DK2968434T3 (https=)
EA (1) EA201591278A1 (https=)
ES (2) ES2639833T3 (https=)
GB (1) GB2530921B (https=)
HK (1) HK1250912B (https=)
HR (2) HRP20171269T1 (https=)
HU (2) HUE036224T2 (https=)
IL (2) IL241549B (https=)
LT (2) LT3290046T (https=)
ME (2) ME03326B (https=)
MX (3) MX373965B (https=)
PL (2) PL3290046T3 (https=)
PT (2) PT2968434T (https=)
RS (2) RS58351B1 (https=)
SG (2) SG10201707598QA (https=)
SI (2) SI2968434T1 (https=)
SM (2) SMT201900141T1 (https=)
TR (1) TR201900319T4 (https=)
WO (1) WO2014145519A2 (https=)
ZA (3) ZA201507604B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015023207A8 (pt) 2013-03-15 2018-01-23 Shire Viropharma Inc composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
NZ719724A (en) * 2013-11-22 2022-08-26 Takeda Pharmaceuticals Co Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
JP6516855B2 (ja) * 2015-02-20 2019-05-22 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１エステラーゼ阻害剤の医薬製剤
HK1250623A1 (zh) * 2015-05-28 2019-01-11 Cornell University 腺相关病毒介导的c1ei递送作为用於血管性水肿的疗法
CA3005906A1 (en) * 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
AU2017305856B2 (en) 2016-08-05 2024-09-12 Csl Behring Gmbh Pharmaceutical formulations of C1 esterase inhibitor
AU2017316513A1 (en) * 2016-08-23 2019-03-28 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency
BR112019023737A2 (pt) * 2017-05-16 2020-05-26 Octapharma Ag Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea
PL3758739T3 (pl) 2018-02-28 2024-09-16 Pharming Intellectual Property B.V. Leczenie i zapobieganie stanowi przedrzucawkowemu
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
WO2019245039A1 (ja) 2018-06-22 2019-12-26 株式会社Ｊｕｎｔｅｎ Ｂｉｏ 感染性免疫寛容を惹起するための組成物
KR20210024048A (ko) 2018-06-22 2021-03-04 가부시키가이샤 준텐 바이오 복합 상태를 갖는 세포 혼합물을 이용한, 면역 관용을 유도하는 항체 및 유도된 림프구, 또한 유도된 림프구를 이용하는 세포 치료제 및 치료법
AU2019288635A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
CN114786724A (zh) * 2019-12-16 2022-07-22 尼普洛株式会社 防聚集剂以及使用该防聚集剂的药物组合物和医疗用设备
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
CN117120076A (zh) * 2021-01-27 2023-11-24 斯帕克治疗公司 用于治疗遗传性血管性水肿的组合物和方法
JP2024525084A (ja) 2021-07-09 2024-07-09 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． Ｃ１エステラーゼ阻害剤によるウイルス感染関連症状の治療
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법
WO2025090843A1 (en) * 2023-10-27 2025-05-01 Kansas State University Research Foundation Small-molecule inhibitors of c1s protease and classical complement pathway
CN119823254B (zh) * 2025-03-14 2025-06-03 深圳市卫光生物制品股份有限公司 一种c1酯酶抑制剂重组变体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
JP4077030B2 (ja) * 1993-09-01 2008-04-16 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 急性心筋梗塞中の心筋傷害の低減方法
JP2000507204A (ja) 1995-12-18 2000-06-13 ステイヒテイング・サンキン・ブロードボールジーニング Ｃ１―インヒビターの補体及び血液凝固阻害特性の強化
AT409336B (de) 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
ES2299473T3 (es) 2000-01-31 2008-06-01 Pharming Intellectual Property B.V. Inhibidor de c1 humano producido en la leche de mamiferos transgenicos.
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
WO2004034971A2 (en) 2002-09-25 2004-04-29 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
EP1626736B1 (en) 2003-05-16 2020-09-16 Pharming Intellectual Property B.V. C1 inhibitor with short half-life for transient treatment
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
EP1893227A2 (en) 2005-06-06 2008-03-05 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
EP2433642B1 (en) 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
CN101365478B (zh) * 2005-12-21 2016-06-22 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用
AU2006327989B2 (en) 2005-12-21 2012-06-07 Pharming Intellectual Property Bv Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
EP2526962B1 (en) 2007-02-12 2019-08-14 CSL Behring GmbH Therapeutic application of Kazal-type serine protease inhibitors
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI543768B (zh) 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
CN102781471B (zh) 2009-10-16 2016-10-12 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
WO2011116291A1 (en) * 2010-03-18 2011-09-22 Thrombolytic Science International Production of human c1 inhibitor in human cells
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
DK2758076T3 (en) 2011-09-24 2019-04-01 Csl Behring Gmbh COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
DK2793935T3 (en) * 2011-12-22 2016-09-05 Csl Behring Gmbh Use of C1 inhibitor in the treatment of secondary edema in the central nervous system.
WO2013138730A1 (en) 2012-03-16 2013-09-19 Enzon Pharmaceuticals, Inc. Polymeric conjugates of c1-inhibitors
HK1214652A1 (zh) 2013-03-13 2016-07-29 克里蒂科斯有限责任公司 用於检测胰腺癌的方法和组合物
BR112015023207A8 (pt) * 2013-03-15 2018-01-23 Shire Viropharma Inc composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
JP6889626B2 (ja) * 2017-06-29 2021-06-18 トキコシステムソリューションズ株式会社 燃料供給システム
JP6935245B2 (ja) * 2017-06-29 2021-09-15 大和ハウス工業株式会社 収容ラック

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Carter et al. (1988) Eur. J. Biochem., 173 : 163). Im Plasma ist der C1-Esterasehemmer ein stark glycosyliertes Glycoprotein mit ungefähr 76 kDa (Perkins et al. (1990) J. Mol. Biol., 214:751). Die Aktivität eines C1-Esterasehemmers kann durch bekannte Verfahren erfasst werden (siehe z.B. Drouet et al. (1988) Clin. Chim. Acta., 174:121-30
Kibbe, et al., Eds., Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Washington beschrieben
Zuraw et al. (2000) J. Allergy Clin. Immunol. 105: 541-546; Bowen et al. (2001) Clin. Immunol. 98: 157-163
Zuraw, B.L. (2008) N. Engl. J. Med., 359: 1027- 1036

Also Published As

Publication number Publication date
AU2020203183A1 (en) 2020-06-04
HRP20190270T1 (hr) 2019-04-05
US20190160158A1 (en) 2019-05-30
US10080788B2 (en) 2018-09-25
JP2019073546A (ja) 2019-05-16
EP2968434A2 (en) 2016-01-20
JP2016516073A (ja) 2016-06-02
SI2968434T1 (sl) 2017-11-30
DK2968434T3 (en) 2017-09-11
ME02865B (me) 2018-04-20
HUE036224T2 (hu) 2018-06-28
US20170224788A1 (en) 2017-08-10
NZ751555A (en) 2021-07-30
JP6473535B2 (ja) 2019-02-20
PL3290046T3 (pl) 2019-05-31
CA2904543C (en) 2019-10-08
EP3508213A1 (en) 2019-07-10
HUE041837T2 (hu) 2019-05-28
MX2020004724A (es) 2022-01-18
JP6473536B2 (ja) 2019-02-20
SG11201507616VA (en) 2015-10-29
GB201519921D0 (en) 2015-12-23
JP2018119000A (ja) 2018-08-02
WO2014145519A2 (en) 2014-09-18
US20190160157A1 (en) 2019-05-30
IL241549B (en) 2020-08-31
HRP20171269T1 (hr) 2017-11-03
EA201591278A1 (ru) 2016-03-31
SI3290046T1 (sl) 2019-04-30
EP2968434A4 (en) 2016-03-02
MX2015011281A (es) 2016-03-03
EP2968434B1 (en) 2017-06-28
ME03326B (me) 2019-10-20
AU2018229558B2 (en) 2020-03-05
KR20220070049A (ko) 2022-05-27
ES2639833T3 (es) 2017-10-30
JP6877470B2 (ja) 2021-05-26
IL276153A (en) 2020-09-30
MX2021011946A (es) 2021-11-17
PL2968434T3 (pl) 2018-01-31
JP2018119002A (ja) 2018-08-02
JP6877472B2 (ja) 2021-05-26
KR20210129267A (ko) 2021-10-27
MX373965B (es) 2020-07-13
KR20150135242A (ko) 2015-12-02
CY1121653T1 (el) 2020-07-31
AU2018229558A1 (en) 2018-10-04
ZA201806793B (en) 2020-01-29
LT2968434T (lt) 2017-09-25
JP6422520B2 (ja) 2018-11-14
LT3290046T (lt) 2019-03-12
MX389449B (es) 2025-03-20
JP6877471B2 (ja) 2021-05-26
US11534482B2 (en) 2022-12-27
IL276153B (en) 2022-06-01
SMT201700415T1 (it) 2017-11-15
EP3290046B1 (en) 2019-01-02
AU2014232912A1 (en) 2015-09-03
JP2021088599A (ja) 2021-06-10
PT3290046T (pt) 2019-02-18
RS58351B1 (sr) 2019-03-29
US10105423B2 (en) 2018-10-23
PT2968434T (pt) 2017-09-18
CA3054718A1 (en) 2014-09-18
DK3290046T3 (en) 2019-03-18
US20180153972A1 (en) 2018-06-07
GB2530921B (en) 2017-09-20
TR201900319T4 (tr) 2019-02-21
JP2019073545A (ja) 2019-05-16
CN111529708A (zh) 2020-08-14
CN105517559A (zh) 2016-04-20
CY1119419T1 (el) 2018-03-07
JP6473534B2 (ja) 2019-02-20
AU2020203183B2 (en) 2022-06-02
KR102430453B1 (ko) 2022-08-05
ES2713004T3 (es) 2019-05-17
HK1250912B (en) 2020-01-10
KR102579789B1 (ko) 2023-09-15
WO2014145519A3 (en) 2014-12-31
JP2018119001A (ja) 2018-08-02
BR112015023207A8 (pt) 2018-01-23
ZA201706929B (en) 2019-05-29
US20180110844A1 (en) 2018-04-26
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
EP3290046A1 (en) 2018-03-07
JP6184581B2 (ja) 2017-08-23
SG10201707598QA (en) 2017-10-30
US20160015795A1 (en) 2016-01-21
BR112015023207A2 (pt) 2017-11-21
HK1220403A1 (en) 2017-05-05
US11364288B2 (en) 2022-06-21
CA2904543A1 (en) 2014-09-18
US20200261556A1 (en) 2020-08-20
ZA201507604B (en) 2018-05-30
SMT201900141T1 (it) 2019-05-10
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
US20180085441A1 (en) 2018-03-29
KR20210021146A (ko) 2021-02-24
JP2017105847A (ja) 2017-06-15
GB2530921A (en) 2016-04-06
US9616111B2 (en) 2017-04-11
JP2019073544A (ja) 2019-05-16

Similar Documents

Publication Publication Date Title
DE202014011208U1 (de) C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind
EP1687031B1 (de) Pharmazeutische zubereitung enthaltend einen antikörper gegen den rezeptor für einen epidermalen wachstumsfaktor (egf-rezeptor)
DE69618018T2 (de) Arzneimittel enthaltend botulinum toxin oder neurotoxin und herstellungsverfahren
EP1455824B1 (de) Lyophilisierte zubereitung enthaltend antikörper gegen den egf-rezeptor
EP0674525B1 (de) Lagerstabile wässrige pharmazeutische zubereitungen von g-csf
EP0876140B1 (de) Verbesserte kontrastmittenlösungen für die intravasale anwendung
HK1250912A1 (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency
DD298053A5 (de) Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides
DE102004030409A1 (de) Neue Verwendung von Meloxicam in der Veterinärmedizin
HUE033949T2 (hu) Nátrium klorid oldat gyógyszer újraoldására vagy hígítására
DE69717293T2 (de) Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form
EP2679239A1 (de) Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
DE69420872T2 (de) Hgh enthaltende pharmazeutische zubereitungen
EP0602686B1 (de) Lektinkonzentrate aus Mistelextrakten und entsprechende standardisierte, stabilisierte Mistellektinpräparate, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel und deren Verwendung zur Erhöhung der natürlichen Immunresistenz und/oder in der Tumor-Therapie
DE60128399T2 (de) Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen
DE69101784T2 (de) Stabilisierte zusammensetzung enthaltend ein fibroblastwachstumsfaktor.
DE69832165T2 (de) Hgf zur behandlung von akutem nierenversagen
DE69129563T2 (de) Epidermis-Wachstumsfaktor als Arzneimittel zur Wiederherstellung der Neuronen der Substantia nigra in der Behandlung nervenzerstörender Störungen
DE69209486T2 (de) Stabilisierte pharmaceutische Zusammensetzung die nicht-glycozylierte, reduzierte rekombinante human IL-2 umfasst und Verfahren zu ihrer Herstellung
AT515356B1 (de) Stabile alkoholische Lösung von Alprostadil
EP0869811B1 (de) Immunologisch wirksame mistelextraktzubereitungen
WO2001045743A2 (de) Verwendung eines enzyms zur verbesserung der geweberesorption von arzneimitteln
DE202017103487U1 (de) Osmolyt in Kombination mit lipophiler Grundlage
DE102025101336A1 (de) Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse
HK40010873A (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency

Legal Events

Date Code Title Description
R150 Utility model maintained after payment of first maintenance fee after three years
R207 Utility model specification
R151 Utility model maintained after payment of second maintenance fee after six years
R152 Utility model maintained after payment of third maintenance fee after eight years
R071 Expiry of right